Kanghong Pharmaceutical (002773.SZ): Phase I clinical trial application for injectable KH815 was approved by Australian HREC

Zhitong Finance App News, Kanghong Pharmaceutical (002773.SZ) issued an announcement. Recently, the Phase I clinical trial application for injectable KH815 declared by Chengdu Kanghong Biotechnology Co., Ltd. (“Kanghong Biology”), a wholly-owned subsidiary of the company, was approved by the Australian Human Research Ethics Committee.

According to reports, injectable KH815 is a novel dual-payload (dual-payload) antibody conjugate drug (ADC) targeting trophoblast cell surface antigen 2 (TROP2) independently developed by Kanghong Biotech. Its dual load can simultaneously inhibit tumor cells at RNA level and DNA level, and has a dual-effect coordination mechanism.

Furthermore, it can reduce the expression of p-gp and Hsp70 proteins, overcome drug resistance, and increase the sensitivity of cells to chemotherapy drugs. In vitro pharmacodynamics studies have shown that KH815 has nanomol-level killing activity on tumor cells with different levels of TROP2 expression. In vivo pharmacodynamics studies showed that KH815 showed dose-dependent tumor growth inhibition effects in CDX models and PDX models of multiple tumors, and KH815 also showed anti-tumor effects in CDX and PDX models resistant to multiple camptothecin ADCs. The dual-load design is expected to enable KH815 to have a high anti-tumor response rate in humans, and it has therapeutic potential for patients resistant to monocavitracin ADCs.